BACKGROUND: Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-TEQ level on BCR. METHODS: A total of 93 men who underwent RP, with a median of 5.3 years of postoperative follow-up, were included in the study. The dioxin-TEQ level of each patient was measured using intraoperatively harvested abdominal subcutaneous fat. The dichotomous categorization of dioxin-TEQ by the 50th percentile (lowo50% vs highX 50%) was also used to regroup the patient cohort, regardless of the previous history of AO exposure. Comparisons between the dioxin-TEQ levels, clinicopathological characteristics and BCR in AO-exposed and -unexposed men were made to allocate possible risk factors. The multivariable logistic regression model was used to identify significant risk factors associated with BCR, adjusting for other confounding factors. RESULTS: The median dioxin-TEQ level in 37 AO-exposed patients was significantly higher than that in 56 unexposed patients (22.3 vs 15.0 pg g À 1 fat, respectively, Po0.001). The men with AO exposure were more likely to have a high dioxin-TEQ level (Po0.001). Neither AO exposure nor the level of dioxin-TEQ was associated with BCR. Tumor stage (T3/T4 vs T2) and Gleason grade (Gleason X3 þ 4) were independent risk factors for BCR after RP. CONCLUSIONS: Exposure to AO significantly increases the adipose level of dioxin-TEQ in patients treated with RP. However, exposure to AO or a high dioxin-TEQ level was not associated with an increased risk of BCR after RP. This lack of association supports the current conclusion that the evidence of carcinogenicity of AO in prostate cancer patients is not sufficient and remains 'limited'.
INTRODUCTION
Agent Orange (AO) is a defoliant herbicide mixture of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid, which was used extensively during the Vietnam War during [1962] [1963] [1964] [1965] [1966] [1967] [1968] [1969] [1970] [1971] . AO was contaminated with 0.05-50 parts per million of the toxin 2,3,7,8-tetrachlorodibenzodioxin (TCDD) or dioxin. 1 The National Academy of Science has concluded that there is 'limited or suggestive' evidence of an association between AO exposure and prostate cancer. 2 Numerous animal and human studies have shown that dioxin is a weak mutagenic carcinogen acting as a tumor promoter. Dioxin has a long half-life of approximately 7.6 years, and its levels can be measured in adipose tissue decades after AO exposure. 3, 4 The dioxin levels in human blood, milk and adipose tissue have been found to be persistently elevated after 20 years exposure to AO among the Vietnamese. 5 Although earlier studies identified no significantly increased risk of prostate cancer with AO exposure in patients referred for prostate biopsy, 6 more recent work has found that AO exposure is associated with an increased risk of prostate cancer. 7 Furthermore, Chamie et al. also demonstrated that AO was an important predictor of prostate cancer development as well as high-grade and metastatic disease at presentation. 8 Studies from the SEARCH database suggest that patients with AO exposure who have been treated with RP have a shorter PSA doubling time and a significantly increased risk of biochemical progression. 9, 10 However, the determination of AO exposure was based on the patient's reported exposure and was confirmed by whether they had served in an area in which AO had been sprayed, but was not supported by any quantitative measurement of dioxin levels. In the present study, we determine the biological toxicity of AO exposure by using the toxic equivalency (TEQ) value, which measures the combination of TCDD-related compounds activating the aryl hydrocarbon receptor. We sought to determine the association between the adipose dioxin-TEQ levels and reported history of AO exposure and the impact of high dioxin-TEQ levels on biochemical recurrence (BCR).
MATERIALS AND METHODS

Patient selection
Institutional Review Board and Veterans Administration approval was obtained, and all patients provided written informed consent. Data were abstracted from the electronic medical records of patients treated with radical prostatectomy (RP) between April 2005 and September 2009 and included patient age at the time of RP, race, body mass index (BMI), pathological stage, preoperative PSA level, pathological Gleason grade, specimen weight, surgical margin status, follow-up PSA levels and postoperative treatments. Of the 242 men undergoing RP during the study's time frame, we excluded 149 men, comprising men who declined participation, had received preoperative androgen deprivation/radiation therapy, were felt intraoperatively to be so thin that harvesting adipose would compromise wound healing, had intraoperative confirmation of metastatic lymph nodes or had specimens not processed due to technical issues. A total of 93 men were included in the final analyses, and the AO exposure status was obtained from electronic medical records, which the AO office in our facility defines as both patients' reported exposure and military records confirming that they had served in an area in which AO had been sprayed. All patients were followed up for a median period of 5.3 years (range: 2.9-7.4 years) to monitor them for BCR. Patients were grouped by the presence or absence of exposure to AO, low or high dioxin-TEQ level based on its percentile distribution (low o50th percentile, high X50th percentile) and the presence or absence of BCR. Surgical positive margins, extracapsular extension, seminal vesicle invasion and lymph node metastasis were combined as an adverse pathology variable, owing to the small sample size of total patients. The dioxin-TEQ level, age at RP, PSA, BMI and prostate volume were examined as continuous variables. Preoperative PSA level (4.0-9.9, X10), Gleason grade (X4 þ 3,3 þ 4, vs 3 þ 3), adverse pathology (at least one adverse feature vs no adverse features), pathological stage (T3/T4 vs T2), race (black vs non-black) and BMI (25.0-29.9, X30 kg m -2 ) were also examined as categorical variables to determine the distribution of clinicopathological features between different groups.
Dioxin-like TEQ measurement
Approximately 3 g of infraumbilical subcutaneous adipose tissue was obtained intraoperatively during RP from each patient. The adipose samples were immediately frozen to p20 1 C and transported for analysis. Specimens were extracted using dimethyl sulfoxide, and dioxin levels were analyzed using the chemical-activated luciferase expression or CALUX assay (Xenobiotic Detection Systems, Durham, North Carolina), which measures TEQs of compounds that activate this assay. Briefly, this assay is performed by applying the adipose extracts in dimethyl sulfoxide to monolayers of recombinant mouse hepatoma (H1L1.1c2) cells stably transfected with the firefly luciferase gene under transactivational control of the aryl hydrocarbon receptor and incubated at 37 1 C in a humidified CO 2 atmosphere. After incubation, the cells were lysed, and luciferase activity was quantified using a luciferase reagent (Promega, Madison, WI, USA) in a luminometer. The dioxin measurement is reported as TEQ pg g À 1 of fat.
3 Dioxin-TEQ was analyzed as a continuous variable to determine the difference between the men with AO exposure and the men with no AO exposure and the difference between the men with BCR and the men with no BCR. Dioxin-TEQ was also categorized dichotomously on the basis of the median value (Low o50% vs High X 50%) to regroup the patient cohort, regardless of the previous history of AO exposure.
Statistical methods and study end points
The primary study end point was to determine the incidence of BCR after RP among prostate cancer patients who were exposed or unexposed to AO, and with low or high dioxin-TEQ levels. The correlation between dioxin-TEQ levels and AO exposure history was examined using both the Student's t-test (two-tailed) for mean value and the Mann-Whitney U test (two-tailed) for median value. The distribution of clinical characteristics, dioxin-TEQ level, race, PSA category, BMI category and pathological characteristics were examined using two-tailed w test (or Fisher's exact test if no5) between groups. Comparisons of age and prostate volume were made between groups using the Student's t-test (two-tailed). The odds ratio of BCR, associated with AO exposure or dioxin-TEQ level, were determined using a multivariate logistic regression model, adjusting for known predictors, pathological stage and Gleason sum, as well as possible confounding factors, including PSA, age, race, BMI and adverse pathology (Table 4) . A final multivariable logistic regression model for BCR contains only T stage (P-valueo0.001) and the Gleason sum (P-valueo0.05), in addition to the primary interest of this study-AO and dioxin-TEQ levels-based on likelihood ratio tests. All data analyses were performed using the statistical package for the Social Sciences software program (version 20.0; IBM, Armonk, NY, USA), at a significance level of 0.05.
RESULTS
AO exposure and adipose dioxin-TEQ level
The median value of adipose dioxin-TEQ in 93 patients was 17.0 pg g À 1 of fat interquartile range (13.4, 24.9). The dioxin-TEQ in 37 men (40%) with AO exposure (median ¼ 22.3 pg g À 1 fat) was significantly higher than in 56 (60%) unexposed men (median ¼ 15.0 pg g À 1 of fat) (Figures 1a,) Po0.001. Relative to men with no AO exposure, the men with AO exposure were more likely to be older at the time of RP (P ¼ 0.01), non-black (P ¼ 0.01) and have higher mean and median values of dioxin-TEQ (Po0.001). Exposure to AO was not significantly associated with BMI, preoperative PSA, prostate volume, Gleason score, tumor pathological stage and adverse pathology (Table 1 ). There were no significant differences of clinicopathological features between men with low dioxin-TEQ levels and those with high dioxin-TEQ levels, except that the men with high dioxin-TEQ levels were more likely to be older (P ¼ 0.03) and non-black (P ¼ 0.02) ( Table 2) .
Dioxin-TEQ level and BCR During a median follow-up of 64 months (interquartile range 42, 72 months), 21 (23%) men had BCR, including 11 (20%) men in the AO-exposed group and 10 (27%) men in the unexposed group. Reclassification of the same group of BCR patients based on the dioxin-TEQ category yielded 8 men (17%) with low dioxin-TEQ levels and 13 men (28%) with high dioxin-TEQ levels (Table 1 and 2). However, the mean and median values of dioxin-TEQ in the men with BCR was not significantly higher than the mean and median values of dioxin-TEQ in the men with no BCR (Figure 1b , Table 3 ). A history of AO exposure or a high dioxin-TEQ level was not associated with BCR after RP. BCR was correlated with BMI (P ¼ 0.03), biopsy Gleason sum (Po0.001), prostatectomy Gleason sum (P ¼ 0.002), tumor stage (Po0.001), extracapsular extension (Po0.001) and seminal vesicle invasion (Po0.001) ( Table 3) . Neither univariate nor multivariable analyses revealed any significant impact of the measured dioxin-TEQ as a continuous 
DISCUSSION
To the best of our knowledge, the present study is the first investigation that determines the impact of dioxin biological toxicity on the outcome in veterans undergoing RP for prostate cancer. We found that neither dioxin-TEQ levels nor AO exposure were associated with BCR after RP. We also found that tumor stage and Gleason grade X3 þ 4 were the independent risk factors for BCR after RP after adjusting for other clinical variables. The correlation between the duration of Agent Orange exposure and the dioxin-TEQ levels was determined using Pearson correlation. In a study to assess the risk of increased incidence of prostate cancer, the Air Force Health Study assigned veterans to four categories based on individual serum dioxin levels: Comparison (median 4.1 pg g À 1 ), Background (median 5.7 pg g À 1 ), Low (median 14.7 pg g À 1 ) and High (median 45.7 pg g À 1 ) TCDD categories. 11 The median dioxin levels of Low (median 15.0 pg g À 1 ) and high (median 22.3 pg g À 1 ) categories in the present study are comparable to the median levels of 'Low' and 'High' categories in the Air Force Health Study. We found that the reported AO exposure does not necessarily translate into high dioxin-TEQ levels and that dioxin-TEQ levels were not associated with BMI, preoperative PSA, prostate volume, Gleason grade, tumor stage or adverse pathological features. However, the men with AO exposure were more likely than those in the unexposed group to have 'High' dioxin-TEQ levels. These results suggest that AO exposure claimed by veterans is likely to be a valid risk factor for prostate cancer and that measuring dioxin-TEQ levels might be a surrogate for determining the degree of AO exposure.
We previously reported that men with AO exposure and prostate cancer were more likely to be younger at the time of RP, had a lower preoperative PSA level and were more likely to have stage T1 disease. 9 In contrast, the men with AO exposure and RP in the present study are older than the men with no history of AO exposure (60 years vs 57 years); but they are still at similar ages at RP (60 years vs 58 years), compared with the prior report. 9 The age difference in our study may be simply on account of the aging of the Vietnamese veteran population. Chamie et al. reported that patients with AO exposure presented at younger ages with highgrade (Gleason 8-10) disease and metastatic disease. 8 Among the men who underwent RP, we found no difference of the Gleason grade (both biopsy Gleason sum and prostatectomy Gleason sum) between those with and without AO exposure, similar to previous studies. 6, 7, 9, 12 These results suggest that AO exposure significantly increases the adipose dioxin-TEQ level but does not necessarily affect the clinical presentation of prostate cancer veterans who elected to undergo RP.
Two previous SEARCH Database studies found an increased risk (relative risk 1.47) of biochemical progression after RP in men with AO exposure, despite similar clinical and pathological characteristics. 9, 10 In contrast, we observed no statistically significant association between AO exposure and BCR; and we did not find a significantly higher rate of BCR after RP among the men with high dioxin-TEQ levels in comparison with the men with low dioxin-TEQ levels. Not surprisingly, after adjusting for various clinical and pathological variables, only tumor stage and Gleason grade X4 þ 3 were independent risk factors for predicting BCR after RP. These results suggest that pathological features from the surgical specimen are more important than the AO exposure status or dioxin levels for predicting BCR. This notion is supported by studies showing that high Gleason grade carcinoma with a positive surgical margin and at a pathological stage substantially worsens the prognosis of prostate cancer after RP.
13,14 Boffetta et al 15 . critically argued that the increased prostate cancer incidence might reflect more extensive prostate cancer screening practices, resulting in the detection of a large number of early prostate cancers of uncertain clinical significance. 15 Our findings showed almost identical mean values of dioxin-TEQ among the men with BCR and the men with no BCR after RP. The minimal impact of the measured dioxin-TEQ levels on the rate of BCR supports the lack of or 'limited' evidence of any underlying carcinogenic effect of dioxins on prostate cancer pathogenesis and progression. Our observation is consistent with other lines of evidence in occupational and major accident studies that did not unequivocally confirm a causal link between dioxin and cancer risk in humans. 15, 16 Several limitations should be considered when interpreting our data. First, selection bias is a concern. We identified a unique population of only the veterans who underwent RP in a single VA institution. Although the distributions of clinicopathological characteristics in the present study are similar to those of the SEARCH cohort, the present study cannot determine the association between AO exposure and clinicopathological features among all the men with prostate cancer within the VA system. The second limitation is the relatively small size of the patient cohort and the short follow-up time. The follow-up time in our study was not long enough to definitively determine the impact of dioxin-TEQ on BCR-free survival or prostate-cancer-specific survival. Cox regression was also performed to examine the effects of AO exposure and dioxin level on BCR survival, which reached the same conclusion as did the logistic regression (results available upon request). Future multicenter studies would provide more convincing evidence to support the observation from our study. Third, misclassification bias may result from the interpretation of the measurement of dioxin-TEQ. The adipose level of dioxin measured 3-4 decades after exposure might not be accurate and may not be correlated with the initial AO exposure in Vietnam. The total value of TEQ in the present study represented the sum of dioxin-like chemical equivalents, which did not exclude the possibility of the alternative environmental exposure to herbicides or occupational hazard during the post-Vietnam era. Although the TEQ is not always proportionate to AO exposure, 5 a recent study on Vietnamese veterans showed that heavy wartime AO in Vietnam resulted in elevated blood and adipose TCDD levels, but did not result in elevated levels of the 12 other dioxin-like dibenzofurans. 17 This finding suggested that the TEQ is likely to be a good substitute for TCDD. The fourth limitation of this study is the lack of other important confounding clinical variables, such as family history of prostate cancer, smoking history and the level of physical activity after RP.
CONCLUSIONS
Among veterans who undergo RP, exposure to AO significantly increases the dioxin-TEQ level. However, high dioxin-TEQ levels were not associated with an increased risk of BCR. This lack of association supports the current conclusion that the evidence of carcinogenicity of AO in prostate cancer is not sufficient and remains 'limited'.
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